Matthew Goetz

Professor of Oncology and Pharmacology

Mayo Clinic

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Matthew Goetz is a Professor of Oncology and Pharmacology at Mayo Clinic in the United States. His research primarily focuses on breast cancer treatment dynamics, including estrogen receptor-low breast cancer, endocrine therapy, and genomic alterations in circulating tumor DNA. He has authored several pivotal articles examining hormone receptor-positive breast cancer therapies and chemotherapy resistance mechanisms.

Articles (17)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (11)

Lajos Pusztai

Yale University

UNITED STATES

View details

Amy Tang

Tenured Professor

Eastern Virginia Medical School

UNITED STATES

View details

Mariana Chavez Mac Gregor

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Gretchen Purcell Jackson

Vanderbilt University Medical Center

UNITED STATES

View details

Guy Jerusalem

BELGIUM

View details

Robert Gray

Dana-Farber Cancer Institute

UNITED STATES

View details

Irene Dankwa-Mullan

George Washington University

UNITED STATES

View details

Masakazu Toi

JAPAN

View details

Stephen Johnston

Professor of Breast Cancer Medicine

Royal Marsden NHS Foundation Trust

UNITED KINGDOM

View details

Patricia Ganz

Professor

University of California, Los Angeles

UNITED STATES

View details

Eva M. Ciruelos-Gil

Universidad Complutense de Madrid

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Matthew Goetz

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Reply to: “Rethinking Treatment Priorities in Estrogen Receptor–Low Breast Cancer” and “CDK4/6 Inhibitors in Estrogen Receptor–Low Breast Cancer”

Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer

Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer

Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

Anastrozole Regulates Fatty Acid Synthase in Breast Cancer

Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer

Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial

Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside

Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials

Accuracy of an Artificial Intelligence System for Cancer Clinical Trial Eligibility Screening: Retrospective Pilot Study

Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies

Collaborators (11)

Lajos Pusztai

Amy Tang

Mariana Chavez Mac Gregor

Gretchen Purcell Jackson

Guy Jerusalem

Robert Gray

Irene Dankwa-Mullan

Masakazu Toi

Stephen Johnston

Patricia Ganz

Eva M. Ciruelos-Gil

Make your next move.